Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer

Garcia, 2007 Lipton, 2004, Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention, J Support Oncol, 2, 205 Roato, 2008, Osteoclasts are active in bone forming metastases of prostate cancer patients, PLoS One, 3, e3627, 10.1371/journal.pone.0003627 Demers, 2000, Biochemical markers and skeletal metastases, Cancer, 88, 2919, 10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z Conde, 2004, Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy, Urology, 64, 335, 10.1016/j.urology.2004.03.036 Smith, 2001, Low bone mineral density in hormone-naive men with prostate carcinoma, Cancer, 91, 2238, 10.1002/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2 Berruti, 2002, Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy, J Urol, 167, 2361, 10.1016/S0022-5347(05)64985-3 Shahinian, 2005, Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 352, 154, 10.1056/NEJMoa041943 Oefelein, 2002, Skeletal fractures negatively correlate with overall survival in men with prostate cancer, J Urol, 168, 1005, 10.1016/S0022-5347(05)64561-2 Saad, 2007, Pathologic fractures correlate with reduced survival in patients with malignant bone disease, Cancer, 110, 1860, 10.1002/cncr.22991 Pavlakis, 2005, Bisphosphonates for breast cancer, Cochrane Database Syst Rev, 10.1002/14651858.CD003474.pub2 Coleman, 2004, Bisphosphonates: Clinical experience, Oncologist, 9, 14, 10.1634/theoncologist.9-90004-14 Saad, 2008, Cancer treatment-induced bone loss in breast and prostate cancer, J Clin Oncol, 26, 5465, 10.1200/JCO.2008.18.4184 Michaelson, 2007, Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer, J Clin Oncol, 25, 1038, 10.1200/JCO.2006.07.3361 Ishizaka, 2007, Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer, Int J Urol, 14, 1071, 10.1111/j.1442-2042.2007.01911.x Israeli, 2007, The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy, Clin Genitourin Cancer, 5, 271, 10.3816/CGC.2007.n.003 Magno, 2005, Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate, Eur Urol, 47, 575, 10.1016/j.eururo.2005.01.012 Planas, 2009, Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis, BJU Int, 104, 1637, 10.1111/j.1464-410X.2009.08622.x Smith, 2009, Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 361, 745, 10.1056/NEJMoa0809003 Guadalupe-Grau, 2009, Exercise and bone mass in adults, Sports Med, 39, 439, 10.2165/00007256-200939060-00002 Fohr, 2003, Clinical review 165: Markers of bone remodeling in metastatic bone disease, J Clin Endocrinol Metab, 88, 5059, 10.1210/jc.2003-030910 Simmons, 2007, Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy, Eur Urol, 51, 1175, 10.1016/j.eururo.2007.01.015 Smith, 2005, Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, J Clin Oncol, 23, 2918, 10.1200/JCO.2005.01.529 Lipton, 2008, Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid, Cancer, 113, 193, 10.1002/cncr.23529 Brown, 2005, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors, J Natl Cancer Inst, 97, 59, 10.1093/jnci/dji002 Cook, 2006, Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer, Clin Cancer Res, 12, 3361, 10.1158/1078-0432.CCR-06-0269 Smith, 2007, Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer, Urology, 70, 315, 10.1016/j.urology.2007.03.071 Lein, 2007, Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression, Eur Urol, 52, 1381, 10.1016/j.eururo.2007.02.033 Lein, 2009, Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid, Prostate, 69, 624, 10.1002/pros.20917 Noguchi, 2003, Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer, Urology, 61, 993, 10.1016/S0090-4295(02)02583-9 Saad F. N-telopeptide of type I collagen (NTX) response to zoledronic acid in patients with bone metastases from prostate cancer. Proceedings of the Société Internationale d'Urologie (SIU) World Uro-Oncology Update Meeting; November, 2008; Santiago, Chile. [Abstract 411]. Jagdev, 2001, Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease, Ann Oncol, 12, 1433, 10.1023/A:1012506426440 Fizazi, 2009, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J Clin Oncol, 27, 1564, 10.1200/JCO.2008.19.2146 Fizazi, 2009, Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial, J Urol, 182, 509, 10.1016/j.juro.2009.04.023 Zafeirakis, 2010, Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases, Eur J Nucl Med Mol Imaging, 37, 103, 10.1007/s00259-009-1243-5 Leeming, 2006, The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients, Cancer Epidemiol Biomarkers Prev, 15, 32, 10.1158/1055-9965.EPI-05-0492 Costa, 2002, Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status, J Clin Oncol, 20, 850, 10.1200/JCO.20.3.850 Koizumi, 2001, The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone, BJU Int, 87, 348, 10.1046/j.1464-410x.2001.00105.x Zafeirakis, 2010, Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases, Nucl Med Commun, 31, 249, 10.1097/MNM.0b013e328335a5ed Kataoka, 2006, Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen, Clin Oncol (R Coll Radiol), 18, 480, 10.1016/j.clon.2006.02.010 Koopmans, 2007, Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: A longitudinal approach, J Urol, 178, 849, 10.1016/j.juro.2007.05.029 Lyubimova, 2004, Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer, Bull Exp Biol Med, 138, 77, 10.1007/BF02694481 Salminen, 2005, Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer, Acta Oncol, 44, 742, 10.1080/02841860500327586 Jung, 2004, Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications, Int J Cancer, 111, 783, 10.1002/ijc.20314 Jung, 2001, Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer, Clin Chem, 47, 2061, 10.1093/clinchem/47.11.2061 Ramankulov, 2007, Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer, Prostate, 67, 330, 10.1002/pros.20540 Ramankulov, 2007, Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma, J Cancer Res Clin Oncol, 133, 643, 10.1007/s00432-007-0215-z Alibhai, 2006, Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review, Crit Rev Oncol Hematol, 60, 201, 10.1016/j.critrevonc.2006.06.006 Chang, 2003, Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: Implications in the management of prostate cancer, Urology, 62, 29, 10.1016/j.urology.2003.10.006 Kastelan, 2006, Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males, Med Hypotheses, 67, 1052, 10.1016/j.mehy.2006.04.040 Araujo, 2008, Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men, J Clin Endocrinol Metab, 93, 2135, 10.1210/jc.2007-1469 Paller, 2009, Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men, Clin Endocrinol (Oxf), 70, 26, 10.1111/j.1365-2265.2008.03300.x Basaria, 2002, Long-term effects of androgen deprivation therapy in prostate cancer patients, Clin Endocrinol (Oxf), 56, 779, 10.1046/j.1365-2265.2002.01551.x Michaelson, 2004, Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer, Clin Cancer Res, 10, 2705, 10.1158/1078-0432.CCR-03-0735 Brufsky, 2009, Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: A 5-year study (Z-FAST), Cancer Res, 69, 10.1158/0008-5472.SABCS-2067 Taxel, 2010, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer, BJU Int, 10.1111/j.1464-410X.2010.09329.x Greenspan, 2008, Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy, J Clin Oncol, 26, 4426, 10.1200/JCO.2007.15.1233 Smith, 2009, Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer, J Urol, 182, 2670, 10.1016/j.juro.2009.08.048 Ton, 2005, Effects of low-dose prednisone on bone metabolism, J Bone Miner Res, 20, 464, 10.1359/JBMR.041125 Ignatoski, 2009, Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: Interleukin-6 response is a potential early indicator of response to therapy, J Interferon Cytokine Res, 29, 105, 10.1089/jir.2008.0024 Lorente, 1999, Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients, Eur J Nucl Med, 26, 625, 10.1007/s002590050430 Hegele, 2007, Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer, BJU Int, 99, 330, 10.1111/j.1464-410X.2006.06604.x Garnero, 2000, Markers of bone turnover for the management of patients with bone metastases from prostate cancer, Br J Cancer, 82, 858, 10.1054/bjoc.1999.1012 Lipton, 2008, Use of elevated bone turnover to predict bone metastasis, J Clin Oncol, 26, 28s Seibel, 2004, Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate, J Bone Miner Res, 19, 323, 10.1359/JBMR.0301231 Heller, 1979, Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases, Curr Probl Clin Biochem, 9, 249 Berruti, 1999, Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases, Clin Chem, 45, 1240, 10.1093/clinchem/45.8.1240 Koizumi, 2003, Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis, Anticancer Res, 23, 4095 Ali, 2004, Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis, Ann Oncol, 15, 455, 10.1093/annonc/mdh089 Coleman, 2008, Meta-analysis of effects of zoledronic acid on survival in patients with metastatic bone disease and high bone turnover, Cancer Treat Rev, 34, S89, 10.1016/j.ctrv.2008.03.120 Erem, 2002, Relationship of bone turnover parameters, endogenous hormones and vitamin D deficiency to hip fracture in elderly postmenopausal women, Int J Clin Pract, 56, 333, 10.1111/j.1742-1241.2002.tb11270.x Slovik, 1984, Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting, J Clin Endocrinol Metab, 59, 228, 10.1210/jcem-59-2-228 Capeller, 2003, Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer, Anticancer Res, 23, 1011